Key facts
- It has raised $2.9M; the latest was Early Stage VC in Dec 2024.
- Notable investors include Kobe University Capital, Plus Social Investment, RIMIX.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for VC Gene Therapy
- ·The full record, as it builds
Funding rounds
No funding rounds for VC Gene Therapy are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VC Gene Therapy
Operator of a biotechnology company intended for the development of gene therapy. The company develops treatments for the RHO (rhodopsin) gene mutation, which is classified as the overtly inherited type of retinitis pigmentosa, enabling patients to get a convenient treatment for the disease.
- Sector
- Healthcare
- HQ
- Kobe, Japan
- Founded
- 2020
- Website
- vcgt.jp/
- Ownership
- Privately Held (backing)
VC Gene Therapy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VC Gene Therapy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VC Gene Therapy in its N-PORT filings yet. We sweep new filings monthly.